Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 16, 2018. The document serves as a transaction notification under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, detailing specific share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on individual share transactions.
| Instrument | Transaction Type | Transaction Date | Price per Share | Total Volume |
|---|---|---|---|---|
| Ordinary Shares (25p each) | Acquisition via Dividend Re-investment | October 11, 2018 | £14.7623 | 378 shares |
Note: The total volume of 378 shares represents the aggregate of 10 separate transactions by different executives.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine share acquisitions resulting from the re-investment of dividends paid on October 11, 2018, under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment, not open market purchases or sales.
- Participants: Transactions involved 10 senior executives, including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and Company Secretary (Mrs V A Whyte).
- Market Data: The share price at the time of transaction was £14.7623 on the London Stock Exchange (XLON).
- Scope: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.